WilmerHale Advises General Catalyst in Capital Rx's Series C Funding

WilmerHale Advises General Catalyst in Capital Rx's Series C Funding

Client News

Related Solutions

Helping clients launch their businesses and transform their innovative ideas into successful companies.
Comprehensive counseling for healthcare providers, insurers and the companies that supply them with products and services.
Offering a sophisticated, full-service solution to private equity sponsors and entrepreneurs, from initial investment to exit.

On June 13, 2022, Capital Rx, a health technology company, announced that it has secured $106M in Series C funding. General Catalyst, a venture capital firm specializing in early-stage and growth equity investments, was among the investors that contributed to the round of funding. The funding will be used to advance Capital Rx's mission of modernizing prescription and healthcare infrastructure to increase operational efficiency and improve patient care.

The WilmerHale team advising General Catalyst was led by Jason Kropp and Jahnvi Desai.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel